Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.

The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC, with ALK+ mutations. Roche said that the approval makes Alecensa the first ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

The news that you have lung cancer can be scary. It’s hard to know what to do next. Here are a few things to think about. Alecensa (alectinib) is a medicine used for treating certain lung cancers.

Betta noted that Ensacove marks the first innovative targeted lung cancer drug developed by a ... But Roche’s Alecensa, Takeda’s Alunbrig and Pfizer’s third-generation med Lorbrena have ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...